Harvard Bioscience Inc (HBIO)vsMedline Inc. Class A Common Stock (MDLN)
HBIO
Harvard Bioscience Inc
$8.03
-1.47%
HEALTHCARE · Cap: $37.33M
MDLN
Medline Inc. Class A Common Stock
$32.53
+0.43%
HEALTHCARE · Cap: $43.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 33996% more annual revenue ($29.94B vs $87.81M). MDLN leads profitability with a 2.3% profit margin vs -11.9%. MDLN earns a higher WallStSmart Score of 52/100 (C-).
HBIO
Hold36
out of 100
Grade: F
MDLN
Buy52
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 262.0% YoY
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -147.1% — below average capital efficiency
Earnings declined 80.3%
Distress zone — elevated risk
ROE of 6.0% — below average capital efficiency
2.3% margin — thin
Operating margin of 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : HBIO
Revenue growth of 11.1% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bull Case : MDLN
The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : HBIO
The primary concerns for HBIO are Market Cap, Piotroski F-Score, Return on Equity. Debt-to-equity of 5.96 is elevated, increasing financial risk.
Bear Case : MDLN
The primary concerns for MDLN are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 42.6x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
HBIO profiles as a turnaround stock while MDLN is a value play — different risk/reward profiles.
MDLN is growing revenue faster at 11.6% — sustainability is the question.
MDLN generates stronger free cash flow (604M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (52/100 vs 36/100) and 11.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harvard Bioscience Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?